Text Size

A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT00471796
First received: May 9, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

There is supposed that patients with functional esophageal disorders such as functional heartburns and functional chest pain have common underlying mechanisms of symptom generation. These include esophageal dysmotility, non-acidic gastro-esophageal reflux, duodeno-gastro-esophageal reflux, esophageal hypersensitivity, and psychological comorbidity.

The treatment of these patients is the growing challenge in the primary care medicine and in the gastroenterological practice. It was postulated that functional disorders of the esophagus are the main reason for PPI failure in patients with heartburn.

The aim of the study is to evaluate the role of biofeedback in the treatment of patients with functional chest pain and functional heartburns.


Condition Intervention
Chest Pain
Heartburn
 Behavioral: Biofeedback

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Assaf-Harofeh Medical Center:

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. Men and women ages 18-75.
  2. Willing to participate and sign an inform consent.
  3. Having heartburns, acid regurgitations and/or chest pain at least twice a week for at least 3 months.
  4. Ability to stop anti-acid and anti-pain medications for at least two weeks.

Exclusion Criteria:

  1. History of upper gastrointestinal surgery.
  2. Concomitant diseases that may affect esophageal perception (diabetes mellitus, neuropathy).
  3. Concomitant medications that may affect esophageal perception (anti-inflammatory, anti-depressants drugs).
  4. Pregnancy.
  5. Severe conditions such as cardiac failure, renal failure and other that may be contraindication for upper endoscopy.
  6. Erosive esophagitis on upper endoscopy or pathological result of ambulatory 24-hour pH monitoring.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00471796

Contacts
Contact: Michael Shapiro, MD +972-8-9779720 shapirom1@yahoo.com

Sponsors and Collaborators
Assaf-Harofeh Medical Center
Investigators
Principal Investigator: Michael Shapiro, MD Assaf-Harofeh Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00471796     History of Changes
Other Study ID Numbers: NCCP-2
Study First Received: May 9, 2007
Last Updated: May 9, 2007
Health Authority: Israel: Ethics Commission

Keywords provided by Assaf-Harofeh Medical Center:
Patients with functional chest pain and functional heartburns

Additional relevant MeSH terms:
Chest Pain
Heartburn
Pain
Signs and Symptoms
Signs and Symptoms, Digestive

ClinicalTrials.gov processed this record on May 16, 2013